Shares of Moderna Inc. MRNA inched 0.92% higher to $42.57 Monday, on what proved to be an all-around mixed trading session ...

Moderna shares are trading higher by 3.1% Monday afternoon. The CDC reported a significant rise in acute respiratory ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Moderna is still generating decent sales from its COVID-19 vaccine. The biotech has won important clinical and regulatory approvals this year. Moderna's portfolio should look much stronger in a ...

The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the ...

Shares of Moderna Inc. MRNA inched 0.43% higher to $42.18 Friday, on what proved to be an all-around favorable trading ...